8-K: Hepion Pharmaceuticals Announces Results of 2024 Annual Meeting of Stockholders

Hepion Pharmaceuticals held its 2024 Annual Meeting of Stockholders on March 10, 2025, and announced the results of voting on five proposals, including the election of directors, ratification of auditors, executive compensation, warrant share issuance, and a reverse stock split amendment.

Summary

• Hepion Pharmaceuticals held its 2024 Annual Meeting of Stockholders on March 10, 2025.
• As of January 17, 2025, the record date, there were 6,958,530 shares of common stock outstanding, including shares issuable upon conversion of Series A Preferred Stock.
• Stockholders voted on five proposals.
• The first proposal was to elect four directors: John P. Brancaccio, Timothy Block, Kaouthar Lbiati, and Michael Purcell, all of whom were elected.
• The second proposal was to ratify the appointment of Grassi & Co., CPAs, P.C, as the company's independent auditors for the fiscal year ending December 31, 2024, which was ratified.
• The third proposal was to approve, on an advisory basis, the compensation of the company's named executive officers (say-on-pay), which was approved.
• The fourth proposal was to approve the full issuance of shares of common stock upon exercise of the Series A and Series B Warrants, which was approved.
• The fifth proposal was to approve an amendment to the company's Certificate of Incorporation to effect a reverse stock split at a ratio of between 1-for-10 and 1-for-50, with the ratio and timing to be determined by the Board, which was approved.

Sentiment

Score: 7

Explanation: The document reports standard corporate governance procedures and the successful passage of routine proposals, indicating a stable and well-managed company from an investor's perspective.

Positives

• All proposed resolutions, including the election of directors, ratification of auditors, say-on-pay, warrant share issuance, and reverse stock split amendment, were approved by the stockholders.

Future Outlook

The Board of Directors will determine the specific ratio and timing of the reverse stock split, if it is to be implemented.

Industry Context

Annual meetings and voting on key proposals are standard practice for publicly traded companies to ensure shareholder participation in corporate governance.

Stakeholder Impact

• Shareholders have approved key proposals, influencing the company's direction.
• The reverse stock split, if implemented, could affect the stock price and shareholder equity.

Next Steps

• The Board will determine the ratio and timing of the reverse stock split, if any.
• The elected directors will serve until the next annual meeting.
• Grassi & Co., CPAs, P.C, will serve as the independent auditors for the fiscal year ending December 31, 2024.

Key Dates